- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Syner-G Biopharma Group Appoints Ron Kraus as CEO
Kraus brings more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, sales, operations, and various support functions.
Syner-G BioPharma Group announced that Ron Kraus has joined the company as Chief Executive Officer (CEO). Kraus has more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, sales, operations, and various support functions.
Prior to joining Syner-G, Kraus was Chief Operating Officer at Cytel. He succeeds Syner-G’s founder, Prabu Nambiar, PhD, MBA, RAC, as CEO.
Read more about Kraus' appointment here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
